275 related articles for article (PubMed ID: 33916984)
1. Functional Roles of SPINK1 in Cancers.
Lin TC
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916984
[TBL] [Abstract][Full Text] [Related]
2. Identification and Exploration of Serine Peptidase Inhibitor Kazal Type I (SPINK1) as a Potential Biomarker Correlated with the Progression of Non-Small Cell Lung Cancer.
Li D; Zhang X; Ding Z; Ai R; Shi L; Wang Z; He Q; Dong Y; Zhu Y; Ouyang W; He Y
Cell Biochem Biophys; 2022 Dec; 80(4):807-818. PubMed ID: 36194314
[TBL] [Abstract][Full Text] [Related]
3. SPINK1 promotes cell growth and metastasis of lung adenocarcinoma and acts as a novel prognostic biomarker.
Xu L; Lu C; Huang Y; Zhou J; Wang X; Liu C; Chen J; Le H
BMB Rep; 2018 Dec; 51(12):648-653. PubMed ID: 30545439
[TBL] [Abstract][Full Text] [Related]
4. Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.
Mehner C; Miller E; Hockla A; Coban M; Weroha SJ; Radisky DC; Radisky ES
Oncogene; 2020 Oct; 39(42):6606-6618. PubMed ID: 32929152
[TBL] [Abstract][Full Text] [Related]
5. Roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases.
Ohmuraya M; Yamamura K
Exp Anim; 2011; 60(5):433-44. PubMed ID: 22041280
[TBL] [Abstract][Full Text] [Related]
6. Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation, migration, invasion and radiation resistance in rectal cancer patients receiving concurrent chemoradiotherapy: a potential target for precision medicine.
Chen YT; Tseng TT; Tsai HP; Kuo SH; Huang MY; Wang JY; Chai CY
Hum Cell; 2022 Nov; 35(6):1912-1927. PubMed ID: 36053457
[TBL] [Abstract][Full Text] [Related]
7. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
Front Immunol; 2022; 13():923031. PubMed ID: 35924241
[TBL] [Abstract][Full Text] [Related]
8. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
[TBL] [Abstract][Full Text] [Related]
9. Serine Protease Inhibitor Kazal Type 1 (SPINK1) Promotes Proliferation of Colorectal Cancer Through the Epidermal Growth Factor as a Prognostic Marker.
Chen YT; Tsao SC; Yuan SS; Tsai HP; Chai CY
Pathol Oncol Res; 2015 Sep; 21(4):1201-8. PubMed ID: 26037168
[TBL] [Abstract][Full Text] [Related]
10. Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.
Shek FH; Luo R; Lam BYH; Sung WK; Lam TW; Luk JM; Leung MS; Chan KT; Wang HK; Chan CM; Poon RT; Lee NP
Cell Oncol (Dordr); 2017 Oct; 40(5):443-456. PubMed ID: 28631187
[TBL] [Abstract][Full Text] [Related]
11. SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma.
Man KF; Zhou L; Yu H; Lam KH; Cheng W; Yu J; Lee TK; Yun JP; Guan XY; Liu M; Ma S
Nat Commun; 2023 Nov; 14(1):7863. PubMed ID: 38030644
[TBL] [Abstract][Full Text] [Related]
12. miR-5089-5p suppresses castration-resistant prostate cancer resistance to enzalutamide and metastasis via miR-5089-5p/SPINK1/ MAPK/MMP9 signaling.
Wang ZC; Li Y; Wang KL; Wang L; You BS; Zhao DF; Liu ZQ; Fang RZ; Wang JQ; Zhang W; Zhang JM; Xu WH
Aging (Albany NY); 2020 Jul; 12(14):14418-14433. PubMed ID: 32694237
[TBL] [Abstract][Full Text] [Related]
13. Emerging Roles of SPINK1 in Cancer.
Räsänen K; Itkonen O; Koistinen H; Stenman UH
Clin Chem; 2016 Mar; 62(3):449-57. PubMed ID: 26656134
[TBL] [Abstract][Full Text] [Related]
14. The impact of physiological stress conditions on protein structure and trypsin inhibition of serine protease inhibitor Kazal type 1 (SPINK1) and its N34S variant.
Buchholz I; Nagel F; Klein A; Wagh PR; Mahajan UM; Greinacher A; Lerch MM; Mayerle J; Delcea M
Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140281. PubMed ID: 31525466
[TBL] [Abstract][Full Text] [Related]
15. Serine protease inhibitor Kazal type 1 mutations and pancreatitis.
Schneider A
Gastroenterol Clin North Am; 2004 Dec; 33(4):789-806. PubMed ID: 15528018
[TBL] [Abstract][Full Text] [Related]
16.
Lin TC
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326089
[TBL] [Abstract][Full Text] [Related]
17. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor.
Ozaki N; Ohmuraya M; Hirota M; Ida S; Wang J; Takamori H; Higashiyama S; Baba H; Yamamura K
Mol Cancer Res; 2009 Sep; 7(9):1572-81. PubMed ID: 19737965
[TBL] [Abstract][Full Text] [Related]
18. TATI as a biomarker.
Itkonen O; Stenman UH
Clin Chim Acta; 2014 Apr; 431():260-9. PubMed ID: 24583226
[TBL] [Abstract][Full Text] [Related]
19. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of SPINK1-positive prostate cancer.
Ateeq B; Tomlins SA; Laxman B; Asangani IA; Cao Q; Cao X; Li Y; Wang X; Feng FY; Pienta KJ; Varambally S; Chinnaiyan AM
Sci Transl Med; 2011 Mar; 3(72):72ra17. PubMed ID: 21368222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]